Zylorion Receives Approval for Phase II Clinical Study for its Proprietary Almond Therapy™
First of its kind study to investigate the effects of Almond Therapy in TRD patients receiving intranasal esketamine. CALGARY, AB, May 10, 2022 /PRNewswire/ – PsiloTec Health Solutions Inc., operating as Zylorion Health, (“Zylorion” or the “Company”), a mental health care and psychedelic…
Comments Off on Zylorion Receives Approval for Phase II Clinical Study for its Proprietary Almond Therapy™